医健IPO解码|从“魔法子弹”到资本新宠,映恩生物能否穿越市场周期?

21世纪经济报道
15 Apr

21世纪经济报道记者季媛媛上海报道  作为一类新兴的大分子靶向药物,抗体偶联药物(ADC)结合了抗体的靶向能力和细胞毒性药物的杀伤效应,在肿瘤治疗领域展现出了卓越的疗效和巨大潜力,因而被誉为“魔法子弹”。  与此同时,伴随着多款ADC药物的获批上市以及BD交易的不断涌现,ADC药物的商业化前景也得到了广泛验证,ADC已成为肿瘤药物研发领域的“璀璨明星”。   根据Frost & Sullivan的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10